ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John M Wrangle1, Vamsidhar Velcheti2, Manish R Patel3, Elizabeth Garrett-Mayer1, Elizabeth G Hill1, James G Ravenel1, Jeffrey S Miller3, Mohammad Farhad4, Kate Anderton1, Kathryn Lindsey1, Michele Taffaro-Neskey1, Carol Sherman1, Samantha Suriano1, Marzena Swiderska-Syn1, Amy Sion1, Joni Harris1, Andie R Edwards1, Julie A Rytlewski5, Catherine M Sanders5, Erik C Yusko5, Mark D Robinson6, Carsten Krieg1, William L Redmond4, Jack O Egan7, Peter R Rhode7, Emily K Jeng7, Amy D Rock7, Hing C Wong7, Mark P Rubinstein8 1Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA. 4Earle A Chiles Research Institute, Portland, OR, USA. 5Adaptive Biotechnologies, Seattle, WA, USA. 6Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland. 7Altor BioScience, Miramar, FL, USA. 8Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA.